Document is current
Any future updates will be listed below
-
Authors
Takeuchi, Satoshi http://orcid.org/0000-0003-4847-6609
Hirata, Kenji
Magota, Keiichi
Watanabe, Shiro
Moku, Rika
Shiiya, Akihiko
Taguchi, Jun
Ariga, Shin
Goda, Tomohiro
Ohhara, Yoshihito
Noguchi, Takurou
Shimizu, Yasushi
Kinoshita, Ichiro
Honma, Rio
Tsuji, Yasushi
Homma, Akihiro
Dosaka-Akita, Hirotoshi
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000022592 at UMIN JapanDocuments that mention this clinical trial
Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study
https://doi.org/10.1186/s13550-023-01019-9
-
Funding
Funding for this research was provided by:
Pfizer Health Research Foundation (28-22)
- License Information
-
More Information
Article History
Received: 15 May 2023
Accepted: 5 July 2023
First Online: 17 July 2023
Declarations
:
: Approval was obtained from all relevant institutional review boards, and the study was registered with the UMIN Clinical Trials Registry (number 000022592). Informed consent was obtained from all participants. The study was conducted in accordance with the tenets of the Declaration of Helsinki. All collected data will be stored for at least five years at Hokkaido University.
: Patients signed an informed consent form to publish their data and photographs.
: The authors have no conflicts of interest to disclose.
